Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2 Pharmaceutical Investing
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights Biotech Investing
Abbott Announces the U.S. Launch of the IonicRF Generator for Use in Patients Living With Chronic Pain Medical Device Investing
Health Canada Approves MAVIRET® 8-Week Treatment Duration for Treatment-Naïve Patients with Genotype 3 Compensated Cirrhosis Biotech Investing
Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee for DUOBRII - a Novel Topical Antipsoriatic Prescription Drug Medical Device Investing
KEYTRUDA® Plus LENVIMA® Demonstrated Statistically Significant Improvement in Progression-Free Survival , Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients... Pharmaceutical Investing
Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue... Pharmaceutical Investing
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020 Biotech Investing
Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b/3 COVID-19 Human Study Biotech Investing
